KR0138738B1 - Oily preparation and method thereof - Google Patents
Oily preparation and method thereofInfo
- Publication number
- KR0138738B1 KR0138738B1 KR1019930011403A KR930011403A KR0138738B1 KR 0138738 B1 KR0138738 B1 KR 0138738B1 KR 1019930011403 A KR1019930011403 A KR 1019930011403A KR 930011403 A KR930011403 A KR 930011403A KR 0138738 B1 KR0138738 B1 KR 0138738B1
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- heated
- oil mixture
- exceeding
- temperature
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 29
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 21
- 235000009566 rice Nutrition 0.000 claims abstract description 21
- 241000209140 Triticum Species 0.000 claims abstract description 20
- 235000021307 Triticum Nutrition 0.000 claims abstract description 20
- 238000010438 heat treatment Methods 0.000 claims abstract description 19
- 235000013339 cereals Nutrition 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 244000068988 Glycine max Species 0.000 claims abstract description 15
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 15
- 241000207961 Sesamum Species 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000000227 grinding Methods 0.000 claims description 7
- 210000003462 vein Anatomy 0.000 claims description 7
- 239000012254 powdered material Substances 0.000 claims 8
- 241000209094 Oryza Species 0.000 claims 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 36
- 230000003078 antioxidant effect Effects 0.000 abstract description 22
- 240000007594 Oryza sativa Species 0.000 abstract description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- -1 lipid peroxides Chemical class 0.000 abstract description 12
- 239000001301 oxygen Substances 0.000 abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 239000004480 active ingredient Substances 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 244000000231 Sesamum indicum Species 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 230000007903 penetration ability Effects 0.000 abstract description 2
- 238000010899 nucleation Methods 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000014347 soups Nutrition 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 60
- 235000019198 oils Nutrition 0.000 description 60
- 235000006708 antioxidants Nutrition 0.000 description 34
- 241000196324 Embryophyta Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000008159 sesame oil Substances 0.000 description 6
- 235000011803 sesame oil Nutrition 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 2
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 231100000704 bioconcentration Toxicity 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000006477 desulfuration reaction Methods 0.000 description 2
- 230000023556 desulfurization Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000006089 Phaseolus angularis Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000007098 Vigna angularis Species 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products having particular features of form
- B32B3/10—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material
- B32B3/12—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material characterised by a layer of regularly- arranged cells, e.g. a honeycomb structure
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/50—Soya sauce
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
- B29D24/00—Producing articles with hollow walls
- B29D24/002—Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled
- B29D24/005—Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled the structure having joined ribs, e.g. honeycomb
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/06—Production of fats or fatty oils from raw materials by pressing
- C11B1/08—Production of fats or fatty oils from raw materials by pressing by hot pressing
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Mechanical Engineering (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Abstract
유효성분인 항산화물질의 활성도가 높고 질병부위내 세포내부로의 침투력이 높은 오일조제 및 그 제조방법이 제공되는 것으로, 오일조제는 100℃를 초과하지 않는 온도에서 쌀배종 및/또는 밀배종 및 콩을 포함하는 곡물원료를 가열하고, 이를 미세 분말로 하고 국을 첨가하여 양조시키고, 같은 방법으로 가열한 참깨로부터 수득한 오일과 원재료 참깨로부터 수득한 오일을 포함하는 오일혼합물에 상기 양조분말을 첨가하되 미세분말과 오일혼합물의 총량비 오일혼합물의 비가 60 내지 95중량%로 하여 제조하며, 인체내에 생성되는 반은성 산소 및 지질과산화물에 의해 세포조직이 파괴되어 발생되는 여러가지 염증 및 난치병의 예방 및 치료에 사용 가능한 것이다.The present invention provides an oil preparation having a high activity of an antioxidant, which is an active ingredient, and a high penetration ability into cells within a diseased area, and a method for preparing the oil, wherein the oil preparation includes rice seeding and / or wheat seeding and soybean seeding at a temperature not exceeding 100 ° C. Heating the grain raw material comprising a fine powder, it is brewed by the addition of soup, and the brewing powder is added to an oil mixture comprising the oil obtained from the sesame heated in the same way and the oil obtained from the raw sesame. The total amount of the fine powder and the oil mixture ratio of 60 to 95% by weight of the oil mixture, which is used for the prevention and treatment of various inflammations and incurable diseases caused by the destruction of cellular tissues by semi-negative oxygen and lipid peroxides produced in the human body. It is available.
Description
본 발명은 오일 조제(Oily Preparation) 및 그의 제조방법에 관한 것으로, 특히 인체내에서 반응성산소 및 지질과산화물의 생성을 억제시키는 물질을 유효성분으로 포함하는 오일 조제에 관한 것이다. 이하에서는 이 물질을 항산화물질이라 칭하기로 한다.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to oil preparation and a method for preparing the same, and more particularly, to an oil preparation including a substance which inhibits the production of reactive oxygen and lipid peroxides in the human body. Hereinafter, this substance will be referred to as an antioxidant.
최근 인체내에서 생성되는 반응성산소 및 지질과산화물에 의한 제포조직의 파괴로 일어나는 여러가지 염증 및 난치병, 예를들면 만성 과절루마티즘, 혈전성정맥염, 진행성 전신계 피부경화증, 뷰르거병, 레이노병, 불응성 피부궤양 등을 예방 및 치료하는데 사용되어 탁월한 효능을 보이는 항산화물질에 대한 관심이 고조되고 있다.Inflammation and refractory diseases caused by the destruction of defoamers caused by the reactive oxygen and lipid peroxides produced recently in the human body, such as chronic hypersection, thrombophlebitis, progressive systemic sclerosis, Burger's disease, Raynaud's disease, refractory There is a growing interest in antioxidants, which have been used to prevent and treat skin ulcers.
본 발명자들은 상기한 항산화물질이 식물체내에 있는 플라보노이드, 폴리페놀, 탄닌, 토코페롤, 비타민 B1등과 같은 저분자량 물질을 포함하고 있고 이들을 약으로 또는 건강식품으로 하여 구강을 통해 섭취하면 체내에서 상기에 언급한 반응성산소 및 지질과산화물의 생성을 억제할 수 있다는 사실을 확인하였다. (참조 : Journal of Japan Pharmacist Association, No. 39. Vol. 12, Supplement, Bioavailability of SOD (Superoxide Dismtasc) and crude drug, PP-1097-1119, Published on December 1, 1987).The present inventors referred to above in the body when the above-described antioxidants include low molecular weight substances such as flavonoids, polyphenols, tannins, tocopherols, vitamin B 1 in the plant and can take in through the mouth with them as drugs or as a health food It was confirmed that the production of reactive oxygen and lipid peroxides can be suppressed. (Reference: Journal of Japan Pharmacist Association, No. 39. Vol. 12, Supplement, Bioavailability of SOD (Superoxide Dismtasc) and crude drug, PP-1097-1119, Published on December 1, 1987).
항산화물질을 포함하는 조제로서 일본특허 제1366268호의 식물영양소와 니와씨의 일본 미심사특허공개 제63-79834호에 기술된 항산화조성물이 통상 알려져 있다.As a preparation containing an antioxidant, the antioxidant composition described in Japanese Unexamined Patent Publication No. 63-79834 of Niwa Seed and Plant Nutrients of Japanese Patent No. 1366268 is usually known.
상기 1366268호의 식물영양소는 볶은 현미가루와 콩가루를 녹차가루와 혼합하고 ; 이 혼합물에 국균류(Koji fungus)를 소량으로 첨가하고 ; 그리고나서 이 분말혼합물을 참기름과 콩기름의 혼합액에 약 4일간 침지시켜 유효성분을 추출하고 ; 원심분리하여 침전물을 제거하고 ; 및 젤라틴 등으로 만들어진 캡슐내에 잔류 오일물질을 포장하는 것에 따라 수득된다.Plant nutrients of No. 1366268 include roasted brown rice flour and soybean flour mixed with green tea powder; To this mixture a small amount of Koji fungus is added; Then, the powder mixture is immersed in the mixed solution of sesame oil and soybean oil for about 4 days to extract the active ingredient; Centrifugation to remove precipitates; And packing the residual oily substance into capsules made of gelatin and the like.
상기 63-79834호의 항산화조성물은 식물종자 또는 그 배종을 타거나 눌지 않도록 약하게 가열시키고 ; 이어서 미생물을 가하여 이 가열처리된 식물재료를 양조하고 ; 및 거리에 역시 약하게 가열처리한 식물로 부터 수득한 식물유를 첨가하는 것에 따라 제조된다. 선택적으로 비타민 C, 비타민 C 유도체 또는 이들을 포함하는 식물체가 조성물에 첨가되기도 한다.The antioxidant composition of 63-79834 is lightly heated so as not to burn or crush the plant seed or its seed; Microorganisms are then added to brew the heat treated plant material; And vegetable oils obtained from plants that have also been slightly heat-treated to the streets. Optionally, vitamin C, vitamin C derivatives or plants containing them may be added to the composition.
식물종자로는 상술한 플라보노이드, 폴리페놀, 탄닌, 코토페롤, 비타민 B1등과 같은 항산화물질을 포함하는 종자, 예를들면 쌀, 밀, 보리, 콩, 아드주끼 콩(adzuki bean), 옥수수, 정맥, 완두콩이 사용된다. 식물유로는 콩기름, 참기름, 면실유, 옥수수기름, 잇꽃기름, 달맞이 꽃기름, 쌀겨기름, 평지기름, 올리브유 등이 사용된다.Plant seeds include seeds containing antioxidants such as flavonoids, polyphenols, tannins, cotoperols, vitamin B 1 and the like, such as rice, wheat, barley, soybeans, adzuki bean, corn, and veins. Peas are used. Vegetable oils include soybean oil, sesame oil, cottonseed oil, corn oil, safflower oil, evening primrose oil, rice bran oil, flat oil and olive oil.
그러나, 상기 1366268호의 식물영양소는 식물원재료를 가공하는 방법이기 때문에 항산화 활성이 낮다.However, the plant nutrient of 1366268 has a low antioxidant activity because it is a method of processing plant raw materials.
니와의 63-79834호 항산화조성물은 원료식물재료를 원적외선으로 타거나 눌지 않도록 약하게 가열하며, 따라서 고온으로 인한 항산화물질의 불황성화를 막고, 그 원재료를 낮은 분자량의 유효성분으로 유리 전환시키고, 및 이 가열처리 재료를 양조시켜 저분자량의 유효성분으로 더욱 유리 전환시키는 것에 따라 항산화물질의 활성을 괄목하게 증가시켜 그와같은 문제를 피하였다.Niwa's 63-79834 antioxidant composition weakly heats the raw plant material to avoid burning or crushing it in the far infrared, thus preventing the desulfurization of antioxidants due to high temperatures, and glass-converting the raw material to low molecular weight active ingredients, and This problem was avoided by significantly increasing the activity of the antioxidants as the heat treatment material was brewed to further freely convert to low molecular weight active ingredients.
그러나 그 이후 본 발명자의 계속된 연구에 따르면, 비록 상술한 항산화물질이 시험관 튜브내에서 반응성산소 및 지질과산화물의 생성을 괄목하게 억제시키고 있지만 인체내에서는 항산화활성이 충분하게 발현되지 못함을 확인하였다.However, subsequent studies by the present inventors have confirmed that although the above-mentioned antioxidants significantly inhibit the production of reactive oxygen and lipid peroxides in the test tube, the antioxidant activity is not sufficiently expressed in the human body.
반응성산소 및 지질과산화물로 인한 염증 등과 같은 질병으로 고통받는 세포내부에 항산화물질이 도달토록 하기위해서는 세포들의 표면을 카버하는 세포막을 통하여 이를 통과시키는 것이 필요하다고 생각된다. 그러나 인간의 세포막은 오일과 지방성분이 풍부하여 오일물질만이 통과를 허용하는 특징이 있으며, 따라서 낮은 함량의 오일물질을 갖는 상술한 항산화 조성물은 세포막을 통하여 세포내부로 침투하는 능력이 낮다.In order for antioxidants to reach inside cells suffering from diseases such as inflammation caused by reactive oxygen and lipid peroxides, it is necessary to pass them through the cell membrane covering the surface of the cells. However, human cell membranes are rich in oils and fats, so that only oily substances are allowed to pass. Therefore, the above-mentioned antioxidant composition having a low amount of oily substance has a low ability to penetrate into the cells through the cell membranes.
따라서 본 발명자들은 원재료로서의 식물종의 선택 및 그 제조방법에 있어 보다 개선을 함으로써 항산화 조성물의 세포벽 통과능력을 향상시키기 위하여 연구를 계속하였다. 결과적으로 유효성분으로의 항산화물질의 활성도가 높고 질병으로 고통받는 세포내부로 침투능력이 높은 오일조제를 얻고 본 발명을 완성하였다.Therefore, the present inventors continued to improve the cell wall passage ability of the antioxidant composition by further improving in the selection of a plant species as a raw material and a manufacturing method thereof. As a result, an oil preparation having high antioxidative activity as an active ingredient and having high permeability into cells suffering from diseases was obtained and completed the present invention.
본 발명의 목적은 유효성분으로 항산화물질의 활성도가 높고 질병위치 부위의 세포내부로 침투력이 높은 오일조제 및 그 제조방법을 제공하는 것이다.It is an object of the present invention to provide an oil preparation having high antioxidative activity as an active ingredient and a high penetration force into a cell at a disease site and a preparation method thereof.
본 발명의 오일조제를 제조하는 방법은, 100℃를 초과하지 않는 온도에서 쌀배종 및/또는 밀배종, 및 콩을 가열하고 ; 이 가열된 재료내에 국(Koji)을 첨가하고 ; 이들 혼합물을 양조시키고 ; 이어서, 혼합물을 분말화하고 ; 및 수둑한 분말혼합물을 100℃를 초과하지 않는 온도에서 가열한 참깨로 부터 얻은 기름과 원참깨로 부터 얻은 기름을 포함하는 오일혼합물에 첨가하는 단계로 구성되는 것으로, 여기에서 분말혼합물과 오일혼합물의 총량에 대한 오일혼합물의 비는 60 내지 95중량% 이다.The method for producing the oil preparation of the present invention comprises heating rice seedlings and / or wheat seedlings and soybeans at a temperature not exceeding 100 ° C; Koji is added to this heated material; Brewing these mixtures; The mixture is then powdered; And adding the steamed powder mixture to an oil mixture comprising oil obtained from sesame and oil obtained from sesame seeds heated at a temperature not exceeding 100 ° C., wherein the powder mixture and oil mixture The ratio of oil mixture to the total amount is 60 to 95% by weight.
상기 쌀배종, 밀배종 및 콩 이외에도, 일본 미심사 특허출원 공개번호 제63-79834에 기술되어 있는 식물종들, 즉, 보리, 아드주끼콩, 옥수수, 정맥, 완두콩 등이 풍부한 항산화물질을 포함하고 있어 또한 거론될 수 있지만, 본 발명자들의 연구에 따르면 쌀배종, 밀배종 및 콩이 가장 바람직한 재료임이 밝혀졌다.In addition to the rice seedlings, wheat seedlings and soybeans, the plant species described in Japanese Unexamined Patent Application Publication No. 63-79834, ie, barley, red bean beans, corn, veins, peas, etc., are rich in antioxidants. Although it can also be discussed, our studies have found that rice seedlings, wheat seedlings and soybeans are the most desirable materials.
쌀배종, 밀배종 및 콩 다음에는 쌀겨, 정맥 및 밀을 들 수 있다. 따라서 원재료로서 쌀겨, 정맥 및 밀 중 적어도 하나가 쌀배종 및/또는 밀배종과 함께 포할될 수 있다. 어떤 경우든 곡물원재료내에서 배종(쌀배종 및/또는 밀배종) 의 비율이 중량비로 적어도 1% 이상 또는 1% 와 함께 하는것이 바람직하다.Rice seedlings, wheat seedlings and soybeans are followed by rice bran, veins and wheat. Thus, at least one of rice bran, veins and wheat as raw materials may be included with rice seedlings and / or wheat seedlings. In any case, it is preferable that the proportion of seed (rice seed and / or wheat seed) in the grain raw material is at least 1% or 1% by weight.
상술한 곡물원재료내의 항산화물질은 다른 물질과 함께 복잡한 거대분자 구조의 폴리머를 형성하고 있어서 그 자체 활성은 없으며, 따라서 저분자량의 항산화물질로 분리되도록 하기위해 약하게 가열하는 등의 수단을 이용하여 거대분자쇄를 절단시키는 것이 필요하다. 그러나 만약 가열온도가 너무 높으면 저분자량 항산화물질이 비활성화 되기때문에 이 사실을 감안하여 가열조건을 선택할 필요가 있다.The antioxidants in the above-mentioned grain raw materials, together with other substances, form complex macromolecular structure polymers, and thus have no activity on their own. Therefore, the macromolecules may be macromolecules by means of light heating such that they are separated into low molecular weight antioxidants. It is necessary to cut the chains. However, if the heating temperature is too high, low molecular weight antioxidants are deactivated, so it is necessary to select the heating conditions in consideration of this fact.
그와같은 조건을 만족시키기 위해서는 100℃를 초과하지 않는 온도에서 충분히 긴 시간동안 곡물원료를 가열시키는 것이 필요하다. 구체적으로 곡물원재료는 바람직하게 4~14 μm 파장의 원적외선을 방출하는 도기 등과 같은 세라믹 용기내에 안치시키고 약 90~96℃의 온도를 유지하며 서서히 저어주어 가열을 진행한다.In order to satisfy such conditions, it is necessary to heat the grain material for a sufficiently long time at a temperature not exceeding 100 ° C. Specifically, the grain raw material is preferably placed in a ceramic container such as pottery, which emits far infrared rays having a wavelength of 4 to 14 μm, and gradually stirs while maintaining a temperature of about 90 to 96 ° C. to proceed with heating.
가열시간은 곡물종의 종류에 따라 달라지기 때문에 일률적으로 정의될 수 없으나 약30분 내지 3시간이 바람직하다. 덧붙여 말하면 가열방법은 곡물원료내의 항산화물질이 그 불황성화가 방지되는 저분자물질로 충분하게 분리될수만 있다면 상술한 방법에만 한정되지 않는다.Since the heating time depends on the type of grain species, it cannot be defined uniformly, but is preferably about 30 minutes to 3 hours. Incidentally, the heating method is not limited to the above-described method as long as the antioxidant material in the grain raw material can be sufficiently separated into the low molecular material to prevent its desulfurization.
상술한 가열처리 후 원재료에 국(Aspergillus orizae)을 첨가하여 양조시킨다. 양조 조건은 20~36℃에서 약 2~6 일간이 좋다. 양조작업은 발효기를 사용하여 수행할 경우 약 2 내지 3시간이면 충분하다. 이 양조작업은 곡물원료내의 항산화물질이 저분자량 물질로 해리 및 전환하는 것을 보다 촉진시켜기 위하여 수행하는 것이며, 이 양조단계를 통하여 항산화물질의 활성도는 가열처리전의 원재료와 비교하여 비약적으로 항진된다.After the heat treatment described above is added to the raw material (Aspergillus orizae) to brew. Brewing conditions are good at about 2-6 days at 20-36 degreeC. Brewing is about 2 to 3 hours is sufficient when carried out using a fermentor. This brewing operation is carried out to further promote the dissociation and conversion of the antioxidants in the grain raw material to low molecular weight substances. Through this brewing step, the activity of the antioxidants is dramatically increased compared to the raw materials before the heat treatment.
다음에 양조된 재료는 분쇄하여 미세분말화한다. 분쇄작업은 상업적으로 이용가능한 분쇄기를 사용하여 수행될 수 있다. 그러나 어떤 형태의 분쇄기는 사용하는 동안 높은온도를 발생하는데 이것은 항산화물질을 불황성화시킨다. 따라서 사용시에 고온을 발생시키지 않는 것을 사용하는것이 바람직한 바, 예를들면 맷돌(stone mill)을 사용하는 것이다.The brewed material is then ground to fine powder. Grinding can be performed using a commercially available mill. However, some types of mills generate high temperatures during use, which deoxidize antioxidants. Therefore, it is preferable to use one that does not generate high temperature in use, for example, to use a mill mill.
다음에 가열된 참깨로 부터 수득한 오일(이하 참깨 페이스트 오일이라 함)에 원참깨로 부터 수득한 오일을 적정비로 혼합한 오일을 준비하고, 상술한 미세분말을 상기 오일혼합물에 첨가한다. 참깨 페이스트 오일은 100℃를 초과하지 않는 온도에서 충분히 긴시간 동안 서서히 원료참깨를 가열하고 이를 분쇄압착하여 수득하는 오일이지만, 참깨를 분쇄하여 형성되는 미세고형물이 그대로 남아있어 그 외관은 페이스트형상 것이다. 이 참깨 페이스트 오일은 저분자량 항산화물질을 풍부하게 포함하고 있어, 그것을 사용하여 높은 활성도의 항산화물질을 갖는 오일조제를 수득할 수 있는 것이다.Next, an oil obtained from heated sesame seeds (hereinafter referred to as sesame paste oil) is prepared by mixing an oil obtained from raw sesame seeds in an appropriate ratio, and the fine powder described above is added to the oil mixture. Sesame paste oil is an oil obtained by gradually heating the raw sesame seeds and grinding and pressing them for a sufficiently long time at a temperature not exceeding 100 ° C., but the fine solids formed by grinding sesame seeds remain intact and their appearance is paste-like. This sesame paste oil contains abundantly low molecular weight antioxidants and can be used to obtain oil preparations having high activity antioxidants.
그러나 이 참깨 페이스트 오일은 고점도이고 오일방울의 크기도 커서 상술한 미세분말에 이 참깨페이스트 오일만 첨가한 조제는 질병부위의 세포내부에의 침투력이 불량하게 된다. 그러나 원재료 참깨로 부터 수득한 참깨오일이 참깨 페이스트 오일에 첨가되면 오일방울의 크기가 작아질 수 있고 질병부위의 세포내부에의 침투력이 향상된다.However, this sesame paste oil has a high viscosity and a large oil droplet size, so that the preparation containing only the sesame paste oil in the fine powder described above has poor penetrability into the cells of the diseased area. However, when sesame oil obtained from raw sesame seeds is added to sesame paste oil, the size of oil droplets can be reduced and the penetration of diseased areas into cells is improved.
원재료 참깨로 부터 채집한 오일은 원재료 참깨를 그대로 분말화하고 이를 압착시킨 뒤 고형물을 제거하여 수득하는 오일로서 상업적으로 허용되고 있는 통상의 참깨오일 이다. 통상의 참깨오일에 대한 참깨 페이스트 오일의 혼합비는 첨가되는 미세분말의 양에 따라 역시 달라지기 때문에 일률적으로 정의될 수는 없다. 바람직하게는 참깨 페이스트 오일 1중량부에 대하여 통상의 참깨오일은 1 내지 3 중량부의 비로 하는것이 좋다.Oil collected from raw sesame seeds is a conventional sesame oil that is commercially acceptable as an oil obtained by powdering raw sesame seeds, pressing them, and removing solids. The mixing ratio of sesame paste oil to conventional sesame oil cannot be defined uniformly since it also depends on the amount of fine powder added. Preferably, the sesame paste oil is a ratio of 1 to 3 parts by weight based on 1 part by weight of sesame paste oil.
거기에 첨가되는 미세분말에 대한 오일혼합물의 비는 혼합오일이 양자의 총량비 60 내지 95중량%가 되도록 한다. 만약 오일혼합물이 60중량% 이하이면 세포막을 통과하는 능력이 불량하고, 반대로 95중량%를 초과하면 유효성분으로서의 항산화물질 농도가 낮게되어 반응성산소 및 지질과산화물의 생성억제효과가 또한 감소하게 된다.The ratio of the oil mixture to the fine powder added thereto causes the mixed oil to be 60 to 95% by weight of the total amount of both. If the oil mixture is 60% by weight or less, the ability to pass through the cell membrane is poor, on the contrary, if it exceeds 95% by weight, the concentration of antioxidants as an active ingredient is low, and the inhibitory effect of the production of reactive oxygen and lipid peroxide is also reduced.
구강을 통하여 섭취하는 본 발명에 따른 오일조제는 오일혼합물이 만들어는 대로 가능한 한 빨리 거기에 미세분말을 첨가하고 젤라틴 캡슐등에 넣어 제조할 수 있다. 그러나 재료혼합물은 캡슐화하기 전에 바람직하게 20 내지 35℃에서 약 3 내지 30일간, 보다 바람직하게는 28 내지 30℃에서 약 1주일간 숙성시킬 수 있다.The oil preparation according to the present invention to be ingested through the oral cavity may be prepared by adding a fine powder therein and gelatin capsules as soon as possible as the oil mixture is made. However, the material mixture may preferably be aged at 20 to 35 ° C. for about 3 to 30 days, more preferably at 28 to 30 ° C. for about 1 week before encapsulation.
숙성처리를 적용함으로써 항산화물질의 유리 및 저분자량 전환은 미세분말내에 남아있는 국(Koji)에 의해 더욱 진전되며, 그 결과 반응성 성분의 세포내 활성도 및 삼투능력은 보다 향상된다.By applying the aging treatment, the free and low molecular weight conversion of the antioxidants is further advanced by Koji, which remains in the fine powder, and as a result, the intracellular activity and the osmotic ability of the reactive component are further improved.
본 발명의 오일조제는 쌀배종 또는 밀배종 및 콩을 포함하는 곡물원료 및 선택적으로 적어도 하나의 쌀겨, 정맥 또는 밀을 또한 포함할 수 있으며, 이것은 가열 및 양조하지 않고 그대로 미세분말로 하여 상술한 가열 및 양조된 미세분말과 함께 오일혼합물에 첨가된다.The oil preparation of the present invention may also comprise grain raw materials comprising rice seedlings or wheat seedlings and soybeans and optionally at least one rice bran, vein or wheat, which is heated as described above as a fine powder without heating and brewing. And the brewed fine powder is added to the oil mixture.
가열 및 양조되지 않은 곡물원료의 미세분말에서는 유효성분으로서의 항산화물질이 저분자량 물질로 해리 및 전환되지 않는다. 그러나 가열 및 양조된 미세분말과 함께 오일혼합물에 첨가될 때에는 항산화물질의 해리 및 저분자량으로의 전환이 양조된 미세분말내에 남아있는 국(Koji)으로 인하여 캡슐화 이후까지도 점진적으로 진행되며, 그결과 반응성산소 및 지질과산화물의 생성을 억제하는 효과가 오랫동안 지속되는 잇점이 있다.In fine powders of grain raw materials that have not been heated and brewed, the antioxidants as active ingredients do not dissociate and convert into low molecular weight substances. However, when added to oil mixtures with heated and brewed micropowders, the dissociation of antioxidants and conversion to low molecular weights gradually progress even after encapsulation, due to the Koji remaining in the brewed micropowders. The effect of inhibiting the production of oxygen and lipid peroxides has the long lasting advantage.
반대로, 가열 및 양조된 미세분말만을 사용한 오일조제는 캡슐화 이후까지도 계속 진행되는 효소반응 등으로 인하여 유효성분으로서의 항산화물질은 점진적으로 분해되며, 그 결과 발현하는 기간이 미처리 미세분말을 첨가한 것에 비하여 짧다.On the contrary, the oil preparation using only the heated and brewed fine powder gradually degrades the antioxidant as an active ingredient due to the enzymatic reaction which proceeds even after encapsulation. As a result, the expression period is shorter than that of the addition of the untreated fine powder. .
그러나 미처리 미세분말의 첨가량이 과도할 경우 유효성분의 활성도가 감소된다. 따라서 미처리 미세분말의 첨가량은 가열 및 양조된 미세분말 1중량부에 대하여 약 0.5 내지 1중량부가 바람직하다. 덧붙여, 두가지 형태의 미세분말을 포함하는 이 경우에 있어서도 오일혼합물은 총량기준으로 60 내지 95중량% 이다.However, when the amount of untreated fine powder is excessive, the activity of the active ingredient is reduced. Therefore, the amount of untreated fine powder is preferably about 0.5 to 1 parts by weight based on 1 part by weight of heated and brewed fine powder. In addition, even in this case including two types of fine powder, the oil mixture is 60 to 95% by weight based on the total amount.
본 발명에 따라 수득하는 이와같은 오일조제에 있어서 항산화물질의 활성도 및 세포내부에로의 삼투력 두가지 다 높고, 이하에 기술하는 임상시험결과로 부터 명백해지지만 통상의 항염증제로서는 치료효과가 불충분했던 여러가지 염증 및 난치병에 대하여 탁월한 효과를 보인다.In this oil preparation obtained according to the present invention, both the activity of the antioxidant and the osmotic power into the cells are high, and it is evident from the clinical test results described below, but various inflammations in which the therapeutic effect is insufficient as a conventional anti-inflammatory agent. And excellent effect against intractable disease.
본 발명의 오일조제는 젤라틴 등으로 캡슐화될 수 있고 구강을 통해 약으로 복용된다. 덧붙여, 피부염, 간반(chloasma), 주근깨, 또는 주름 등과 같은 변태색소침착의 경우에는 오일조제를 해당부위에 바로 적용해도 좋다. 피부염 등에 더하여, 본 발명의 오일조제는 만성관절루마티즘, 혈전성 정맥염, 진행성 전신계 피부경화증, 뷰르거병, 레이노병, 불응성 피부궤양 등과 같은 성인병 및 난치병에 또한 적용될 수 있다. 본 발명의 조제는 다른 여러가지 오염으로 부터 오는 질병, 화상, 외상, 피로, 숙취, 변비 등의 치료 및 예방에 또한 효과가 있다.The oil preparation of the present invention can be encapsulated with gelatin and the like and is taken as a medicine through the oral cavity. In addition, in the case of metamorphic pigmentation such as dermatitis, chloasma, freckles, or wrinkles, an oil preparation may be applied directly to the corresponding site. In addition to dermatitis and the like, the oil preparation of the present invention can also be applied to adult diseases and intractable diseases such as chronic arthritis, thrombophlebitis, progressive systemic sclerosis, Burger disease, Raynaud's disease, refractory skin ulcers and the like. The preparation of the present invention is also effective in the treatment and prevention of diseases, burns, trauma, fatigue, hangover, constipation, etc. resulting from various other pollutions.
또한 본 발명의 오일조제는 원재료로서 곡물, 국(Koji) 및 참깨만을 사용하기 때문에 부작용이 없으며, 그 결과 건강을 유지하고 증지시키기 위한 건강음식으로 복용하는 것도 가능하다. 조제를 만들때, 보조약제 또는 여러가지 비타민유, 미네랄류 등, 및 향료, 조미료, 색소 등과 같은 건강을 위한 유용한 성분들이 선택적으로 첨가될 수 있음은 말할 것도 없다.In addition, since the oil preparation of the present invention uses only grain, koji and sesame as raw materials, there are no side effects, and as a result, it may be taken as a healthy food for maintaining and certifying health. Needless to say, when preparing a preparation, supplementary supplements or various vitamin oils, minerals, etc., and ingredients useful for health, such as flavorings, seasonings, colorings, etc., may optionally be added.
실시예Example
쌀배종, 콩, 쌀겨, 정맥 및 밀 각각 1부를 4~14μm의 원적외선을 방출하는 도기로 된 단지내에 넣고, 타거나 눌지않도록 서서히 저어주면서 90~96℃의 온도를 3시간 동안 가열하였다. 다음에 국(Koji)을 총량의 3%로 첨가하고 36~40℃의 온도로 72시간 동안 양조시킨 후, 이 양조재료를 맷돌을 이용 미세분말로 하였다. 또 상기에 언급한 다섯종류의 곡물원료를 가열하거나 양조시키지 않은채 맷돌에 갈아서 동일량의 미세분말로 하였다. 한편 참깨를 상기 곡물재료와 같은 방법으로 가열하고 맷돌로 간후 압착하여 참깨 페이스트 오일을 얻었다.One part of each rice seed, soybean, rice bran, vein and wheat was placed in a pot of 4-14 μm far-infrared infrared rays, and heated at a temperature of 90-96 ° C. for 3 hours while slowly stirring to prevent burning or pressing. Next, Koji was added at 3% of the total amount and brewed at a temperature of 36 to 40 ° C. for 72 hours, and this brewing material was made into fine powder using a millstone. The five kinds of grain raw materials mentioned above were ground to millstone without heating or brewing to obtain the same amount of fine powder. Meanwhile, sesame seeds were heated in the same way as the grain material, milled and pressed to obtain sesame paste oil.
다음에 상기 참깨 페이스트 오일 28.1 중량부에 상업적으로 사용되고 있는 참깨오일을 48.9 중량부로 혼합하고, 이 혼합물에 가열양조한 미세분말 11.5중량부 및 미처리 미세분말 11.5중량부를 첨가한 후, 균일하게 혼합하였다. 수득한 혼합물을 28℃에서 1주일간 숙성한 후 젤라틴에 캡슐화하여 오일조제를 수득하였다.Next, 48.9 parts by weight of commercially used sesame oil was mixed with 28.1 parts by weight of the sesame paste oil, and 11.5 parts by weight of heat-brewed fine powder and 11.5 parts by weight of untreated fine powder were added and then mixed uniformly. The resulting mixture was aged at 28 ° C. for 1 week and then encapsulated in gelatin to give an oil preparation.
1. 시험관 테스트1. Test tube test
(1) 오일의 도착 및 침투능력을 시험관 테스트 하기위해 본 실시예의 오일조제를 불포화 지방산(도코사헥사노익산 : docosahexaenoic acid)이 자외선에 의해 발생한 반응성 산소와 반응하여 지질과산화물이 형성되어 있는 TBA(티오바르비투르산 : thiobarbituric acid) 반응계에 첨가하였고 지질과산화물의 생성억제도를 축정하였다.(1) To test the oil's arrival and permeability, the oil preparation of this Example is reacted with unsaturated fatty acid (docosahexaenoic acid) reacted with reactive oxygen generated by ultraviolet rays to form TBA ( Thiobarbituric acid (thiobarbituric acid) was added to the reaction system and the formation of lipid peroxide was inhibited.
즉, 100배로 희석한 디코사헥사노익산 0.1㏄에 본 발명의 오일조제 테스트 샘플 1.8㎎/ml 를 가하고, 생성된 지질과산화물을 TBA 반응으로 측정하였다. TBA 반응에서 0.2ml의 7% 나트륨도데실설페이트, 2ml의 0.1N HCI 및 0.3ml의 포스포텅스틱산을 혼합하고, 여기에 1.8㎎/ml의 테스트샘플을 첨가한 후, 0.67% TBA를 초산과 1:1 로 혼합한 시약 1ml을 가하고, 형광스펙트로포토메터를 사용 515nm에서의 여기(excitation) 및 553nm에서의 방사(emission)를 측정하였다.That is, 1.8 mg / ml of the oil preparation test sample of this invention was added to 0.1 microliters of dicosahexanoic acid diluted 100-fold, and the produced lipid peroxide was measured by TBA reaction. In a TBA reaction, 0.2 ml of 7% sodium dodecyl sulfate, 2 ml of 0.1N HCI and 0.3 ml of phosphotungstic acid were added thereto, followed by addition of 1.8 mg / ml of test sample, followed by 0.67% TBA with acetic acid. 1 ml of the reagent mixed in a 1: 1 ratio was added, and the excitation at 515 nm and the emission at 553 nm were measured using a fluorescence spectrophotometer.
비교예로써 일본특허 제1366268호의 식물 영양소(비교예 1) 및 일본 미심사 특허 출원공개 제63-79834호에 기술된 항산화조성물(비교예 2)이 사용되었고 측정은 같은 방법으로 실시되었다. 결과는 표 1에 정리하였다.As a comparative example, the plant nutrients (Comparative Example 1) of Japanese Patent No. 1366268 and the antioxidant composition (Comparative Example 2) described in Japanese Unexamined Patent Application Publication No. 63-79834 were used, and the measurement was carried out in the same manner. The results are summarized in Table 1.
[표 1]TABLE 1
테스트 결과Test results
테스트 샘플의 어느 것이라도 자외선 조사(1O2) 조사에 의해 불포화 지방산(도코사헥사노익산)으로 부터 지질과산화물(TBA 반응성 물질)의 생성을 현저히 억제 시키고 있지만, 특히 본 발명의 오일 조제는 이같은 생성을 탁월하게 억제 시키고 있다(P〈0.0001). 이 결과는 본 발명의 오일조제가 높은 활성도의 항산화 물질을 가지며 질병을 일으키는 세포 내부로의 침투력이 종래의 조제에 비하여 높다는 사실을 뒷받침 하는 것이다(비교예 1 및 2).Although any of the test samples significantly inhibited the production of lipid peroxides (TBA reactive substances) from unsaturated fatty acids (docosahexanoic acid) by ultraviolet irradiation ( 1 O 2 ) irradiation, in particular the oil preparation of the present invention It is excellent in suppressing the production (P <0.0001). This result supports the fact that the oil preparation of the present invention has a high activity of the antioxidant substance and has a high penetration ability into the cell causing disease (Comparative Examples 1 and 2).
(2) 본 발명의 오일조제내에 포함된 저분자량 항산화 물질이 동위원소(3H)로 표기된 [3,4-3H2]- 항산화 물질로 준비 되었고, 이것을 테스트 튜브내 인간 세포내로 첨가하고, 및 세포벽에 대한 [3H2] 바운드 수(cpm)를 신틸레이션계수기로 측정하였고, 이로써 세포벽에 다다르는 능력이 측정되었다(라벨 붙인 트리튬화티미딘은 2Cl/mM 였다).(2) A low molecular weight antioxidant contained in the oil preparation of the present invention was prepared from [3,4- 3 H 2 ] -antioxidant labeled with isotope ( 3 H), which was added into human cells in a test tube, And [ 3 H 2 ] bound number (cpm) on the cell wall was measured with a scintillation counter, whereby the ability to reach the cell wall was measured (labeled trithiated thymidine was 2Cl / mM).
같은 테스트가 비교예 1 및 2로 역시 수행되었다. 그 결과는 표 2 에 정리하였다. 표 2로 부터 명확한 바와 같이 본 발명의 오일조제는 비교예 1 및 2에 비하여 세포벽에 대한 친화성이 매우 높았다.The same test was conducted with Comparative Examples 1 and 2 as well. The results are summarized in Table 2. As apparent from Table 2, the oil preparation of the present invention had a very high affinity for cell walls as compared with Comparative Examples 1 and 2.
[표 2]TABLE 2
(3) 본 발명의 오일조제를 초음파 처리하고, 반응성산소발생시스팀(뉴트로필 및 크산틴-크산틴산화효소)에 첨가하여 전환 생체 농도가 1.6㎎/ml 가 되도록 하고, 및 3가지 형태의 반응성산소(O2-, H2O2및 OH-)를 무첨가 한 경우(대조표준)와 비교하여 측정하였다. 전환된 생체농도는 하루에 통상 취한양(본 발명의 오일조제의 경우 9g)이 생체내에 흡수 되었을 때 피속에 존재하는 것으로 추정되는 양이다.(3) The oil preparation of the present invention was sonicated and added to a reactive oxygen generation system (neutrophyll and xanthine-xanthine oxidase) to give a conversion bioconcentration of 1.6 mg / ml, and three types of reactivity. Oxygen (O 2- , H 2 O 2 and OH-) was measured in comparison with no addition (control). The converted bioconcentration is the amount assumed to be present in the blood when the amount normally taken per day (9 g for the oil preparation of the present invention) is absorbed in vivo.
세가지 형태의 반응성 산소에 대한 측정 방법은 다음과 같다.The measurement methods for the three types of reactive oxygen are as follows.
O2-에 대해서는, 백만분광광도계를 이용하여 550nm 파장에서 O2-의한 페리치토큼 C의 환원량을 측정하고 O2-의 양으로 전환시키는 방법을 이용하였다.As for O 2 −, a method of measuring the amount of reduction of O 2 − by Perititch C at 550 nm using a spectrophotometer and converting it into the amount of O 2 − was used.
H2O2에 대해서는, H2O2가 과산화효소의 존재하에서 스코폴레틴에 의해 생성되는 형광을 감소시킨다는 사실에 입각, 스코폴레틴과 과산화효소를 사용하고 하다찌사가 제작한 370nm의 발양 및 460nm의 방출을 갖는 분광광도계를 사용하여 스코폴레틴의 형광감소 정도를 측정하였다.For H 2 O 2 , the development of 370 nm produced by Hadachi Corporation using scopoline and peroxidase based on the fact that H 2 O 2 reduces the fluorescence produced by scopoletin in the presence of peroxidase and The degree of fluorescence reduction of scopoletin was measured using a spectrophotometer with an emission of 460 nm.
OH-에 대해서는,- 케토-메치올-부틸산(KMB)이 OH-와 반응하여 에틸렌 가스를 생성하는 원리에 입각, 에틸렌 가스를 히다찌사가 제작한 가스크로마토그라피로 정량하여 OH-로 전환하는 방법을 사용하였다. 같은 테스트가 비교예 1 및 2에 대해서 역시 수행되었다. 결과를 하기 표 3에 정리한다.About OH- Based on the principle that keto-methol-butyl acid (KMB) reacts with OH- to produce ethylene gas, a method of converting ethylene gas into OH- by quantifying gas chromatography produced by Hitachi Corporation was used. The same test was performed for Comparative Examples 1 and 2 as well. The results are summarized in Table 3 below.
[표 3]TABLE 3
테스트 결과Test results
본 발명 오일조제의 항산화효과는 비교예 2에 비하여 다소 떨어지지만 비교예 1보다는 강한 항산화효과를 보였다. 그러나 상기 표 1 및 2에서 명확한 바와 같이 비교예 2는 보다 적은 오일물질 함량을 가지며, 그 결과 질병을 일으키는 세포에 도달하는 능력이 낮다.The antioxidant effect of the oil preparation of the present invention was somewhat inferior to Comparative Example 2, but showed a stronger antioxidant effect than Comparative Example 1. However, as is clear from Tables 1 and 2, Comparative Example 2 has a lower oil content, and as a result, the ability to reach disease-causing cells is low.
따라서 전체적으로 판단할 때 본 발명의 오일조제는 항산화효과가 높고 질병부위 세포내부로의 침투력이 아주 높아 황산화제로서 가장 뛰어난 것이다.Therefore, when judged as a whole, the oil preparation of the present invention is the most excellent as a sulfate agent because of its high antioxidant effect and very high penetration into the diseased cell.
2. 임상테스트2. Clinical test
비스테르로이드계소염제, 스테로이드 및 비교예 2의 항산화조성물중 어느 하나에 대항하여 지금까지 저항하거나 나빠진 만성관절루마티즘, 혈액순환부전, 신장염, 간경변증, 간반, 주근깨 등의 자기면역질환, 교원병 환자 96명에 대하여 치료효과를 조사하였다. 그 결과를 표 4에 정리하였다.Patients with autoimmune diseases, such as chronic arthritis, blood circulation failure, nephritis, cirrhosis, liver circumference, freckles, etc., which have so far resisted or worsened against any of the bisteroid anti-inflammatory agents, steroids and the antioxidant composition of Comparative Example 2 96 The effects of treatment were investigated for the population. The results are summarized in Table 4.
[표 4]TABLE 4
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4-162666 | 1992-06-22 | ||
JP4162666A JP2955126B2 (en) | 1992-06-22 | 1992-06-22 | Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof |
JP92-162666 | 1992-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR940000113A KR940000113A (en) | 1994-01-03 |
KR0138738B1 true KR0138738B1 (en) | 1998-05-15 |
Family
ID=15758977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930011403A KR0138738B1 (en) | 1992-06-22 | 1993-06-22 | Oily preparation and method thereof |
Country Status (20)
Country | Link |
---|---|
JP (1) | JP2955126B2 (en) |
KR (1) | KR0138738B1 (en) |
CN (1) | CN1065433C (en) |
AT (1) | AT406935B (en) |
AU (1) | AU656681B2 (en) |
BE (1) | BE1006911A3 (en) |
CA (1) | CA2098893C (en) |
CH (1) | CH686482A5 (en) |
DE (1) | DE4320526C2 (en) |
DK (1) | DK169714B1 (en) |
ES (1) | ES2049189B1 (en) |
FR (1) | FR2692442B1 (en) |
GB (1) | GB2268185B (en) |
HK (1) | HK1007165A1 (en) |
IS (1) | IS1657B (en) |
IT (1) | IT1266950B1 (en) |
NL (1) | NL193398C (en) |
NO (1) | NO306932B1 (en) |
SE (1) | SE512781C2 (en) |
TW (1) | TW269630B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2946548A (en) * | 1956-09-10 | 1960-07-26 | Lars G V Largelins | Supporting clamp |
GB9509811D0 (en) * | 1995-05-15 | 1995-07-05 | Cerestar Holding Bv | Co-pressing of oilseeds |
DE19715878A1 (en) * | 1997-04-16 | 1998-10-22 | Pharmaberatung Fuer Ernaehrung | Products to aid the treatment of atopic dermatitis |
JPH11269066A (en) * | 1998-03-20 | 1999-10-05 | Kao Corp | Skin-bleaching agent for peroral administration and skin-bleaching food |
AUPP574298A0 (en) * | 1998-09-07 | 1998-10-01 | Jacobs, David Ian | Pharmaceutical preparation |
JP2000159682A (en) * | 1998-09-17 | 2000-06-13 | Kozo Niwa | Method of strengthening antitumor activity of crude drug, composition containing crude drug for strengthening antitumor activity, method of evaluating antitumor effectivity treated by crude drug and method of evaluating antitumor effectivity of crud drug |
JP2000239187A (en) * | 1999-02-22 | 2000-09-05 | Dotto:Kk | Transnasal absorption composition |
JP2001199892A (en) * | 2000-01-17 | 2001-07-24 | Kozo Niwa | Method for enhancing antitumor activity of amygdalin- containing material, composition containing amygdalin- containing material for enhancing antitumor activity, method for evaluating antitumor effectiveness of treatment by amygdalin-containing material, and method for evaluating antitumor effectiveness of amygdalin- contaning material |
JP4621444B2 (en) * | 2004-06-18 | 2011-01-26 | 株式会社ヴァリダックス | Method for producing antitumor substance |
DE102007011985B4 (en) | 2007-03-09 | 2022-10-20 | Markus Greim | Mortar measuring cell for rotation viscometer |
FR2956324A1 (en) * | 2010-01-18 | 2011-08-19 | Valerie Baille | Plant complex, useful to e.g. prepare a composition in pharmaceutical, cosmetic or nutrition, comprises a bamboo polyphenolic extract, a cell preparation of Ginkgo biloba and a rice bran oil preparation |
CN104178334A (en) * | 2013-05-24 | 2014-12-03 | 北京中天金谷粮油工程技术有限公司 | Process for infrared baking of sesame to produce oil |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6020389B2 (en) * | 1983-06-07 | 1985-05-21 | 工業技術院長 | Separation method of tocopherols |
JPS60110269A (en) * | 1983-11-18 | 1985-06-15 | Kimimoto Wada | Preparation of vegetable nutrient |
JPS6236327A (en) * | 1985-08-08 | 1987-02-17 | Kozo Niwa | Chinese herbal remedy |
JPS6379834A (en) * | 1986-09-25 | 1988-04-09 | Kozo Niwa | Active oxygen suppressive composition |
JPH023495A (en) * | 1988-06-13 | 1990-01-09 | Okuno Seiyaku Kogyo Kk | Antioxidant |
JPH0441436A (en) * | 1990-06-04 | 1992-02-12 | Sodetsukusu Kk | Antioxidant composition |
JPH07119176B2 (en) * | 1990-09-28 | 1995-12-20 | アサヒビール株式会社 | Anti-active oxygen acting composition and anti-active oxygen agent containing the same as an active ingredient, food, cosmetics and pharmaceuticals |
JP3357383B2 (en) * | 1991-08-14 | 2002-12-16 | 昌宏 黒田 | Low molecular weight plant composition |
JP2647774B2 (en) * | 1991-11-28 | 1997-08-27 | 株式会社 エイオーエイ・ジャパン | Plant antioxidant composition |
-
1992
- 1992-06-22 JP JP4162666A patent/JP2955126B2/en not_active Expired - Lifetime
-
1993
- 1993-06-21 DE DE4320526A patent/DE4320526C2/en not_active Expired - Lifetime
- 1993-06-21 GB GB9312763A patent/GB2268185B/en not_active Expired - Lifetime
- 1993-06-21 SE SE9302141A patent/SE512781C2/en unknown
- 1993-06-21 DK DK073293A patent/DK169714B1/en not_active IP Right Cessation
- 1993-06-21 NO NO932282A patent/NO306932B1/en not_active IP Right Cessation
- 1993-06-21 IT IT93TO000448A patent/IT1266950B1/en active IP Right Grant
- 1993-06-21 CA CA002098893A patent/CA2098893C/en not_active Expired - Lifetime
- 1993-06-21 CH CH186493A patent/CH686482A5/en not_active IP Right Cessation
- 1993-06-22 AU AU41432/93A patent/AU656681B2/en not_active Expired
- 1993-06-22 IS IS4038A patent/IS1657B/en unknown
- 1993-06-22 CN CN93109052A patent/CN1065433C/en not_active Expired - Lifetime
- 1993-06-22 KR KR1019930011403A patent/KR0138738B1/en not_active IP Right Cessation
- 1993-06-22 BE BE9300641A patent/BE1006911A3/en not_active IP Right Cessation
- 1993-06-22 NL NL9301083A patent/NL193398C/en not_active IP Right Cessation
- 1993-06-22 FR FR9307557A patent/FR2692442B1/en not_active Expired - Lifetime
- 1993-06-22 ES ES09301404A patent/ES2049189B1/en not_active Expired - Fee Related
- 1993-06-22 AT AT0122893A patent/AT406935B/en not_active IP Right Cessation
- 1993-06-22 TW TW082104986A patent/TW269630B/zh not_active IP Right Cessation
-
1998
- 1998-06-24 HK HK98106356A patent/HK1007165A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU596701B2 (en) | Antioxidant composition and production method thereof | |
KR0138738B1 (en) | Oily preparation and method thereof | |
KR102205201B1 (en) | Composition for removing elderly smell and 2-nonenal comprising extract of pepper | |
AU4486299A (en) | Antitumor activity strengthening method of crude drugs, composition containing crude drug strengthening antitumor activity, evaluating method of antitumor effectiveness by crude drug treatment, and evaluating method of antitumor effectiveness of crude drug | |
KR100534074B1 (en) | Cosmetic composition containing grain extract and fermented grain phellinus linteus extract, and cosmetics containing the same | |
JP3386155B2 (en) | Cosmetic cream, cream for preventing or treating freckles, freckles, cream for preventing or treating wrinkles, and cream for preventing or treating sunburn | |
JP2001199892A (en) | Method for enhancing antitumor activity of amygdalin- containing material, composition containing amygdalin- containing material for enhancing antitumor activity, method for evaluating antitumor effectiveness of treatment by amygdalin-containing material, and method for evaluating antitumor effectiveness of amygdalin- contaning material | |
KR101425047B1 (en) | Composition for antioxidant comprising extract or fractions of Rhododendron album Blume as an active ingredient | |
CN108464501B (en) | High-protein weight-losing meal replacement powder and preparation method thereof | |
KR102290223B1 (en) | Composition for antioxidation comprising extracts of Senna obtusifolia, Rubus coreanus and Helianthus tuberosus | |
JPH09143091A (en) | Composition having active oxygen-scavenging ability | |
KR100918616B1 (en) | A composition comprising Ortilia secunda extract as an active ingredient | |
KR101433726B1 (en) | Composition for antiaging comprising extracts or fractions of Diospyros blancoi A. DC. as an active ingredient | |
JP2000224970A (en) | Active oxygen-depressing composition, medicine for external use, alcoholic drink and production of the same composition | |
KR101440483B1 (en) | Composition for antiaging comprising extract or fraction of Ardisia tinctoria Pit. as an active ingredient | |
KR20090041532A (en) | A composition comprising pentaphylloides fruticosa extract as an active ingredient | |
JP2003342198A (en) | Vehicle composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130207 Year of fee payment: 16 |
|
EXPY | Expiration of term |